Pain medicine

Transcutaneous electrical nerve stimulation and catheter-related bladder discomfort following transurethral resection of bladder tumour: A randomised controlled trial

Eur J AnaesthesiolPublished Randomised controlled trial

Primary resultResult — go to the resultRelative risk 0.294 95% CI 0.161–0.536

Authors' conclusion

TENS reduced moderate to severe CRBD, decreased postoperative pain, and increased patient satisfaction after TURBT.

Study context

Population
Patients requiring urinary catheterisation after transurethral resection of bladder tumours (TURBT), large university tertiary hospital, October 2022 to March 2023
Participants
56 vs 56
Comparison
Transcutaneous electrical nerve stimulation (TENS) vs control
  • TENSn = 56
  • Controln = 56reference
Primary endpoint
Moderate to severe catheter-related bladder discomfort (CRBD) (self-reported CRBD symptoms with or without behavioural response)
Follow-up
Immediately postoperatively
Methodological detailssingle-centre
  • Single-centre

Primary result

As reported in the abstract

Relative risk

0.294

95% CI 0.161–0.536

P < 0.001

Events by treatment group

TENS vs Control
RR 0.294 (95% CI 0.161–0.536); P < 0.001

Secondary outcomes

OutcomeTENSControlRR (95% CI)P value
Moderate to severe CRBD · 1 h postoperativelyAbsolute risk reduction = 0.27; NNT = 3.71.8%28.6%0.06 (0.01–0.46)P < 0.001
OutcomeTENSControlEstimateP value
Postoperative pain score · 1 h1.8 ± 0.62.2 ± 0.4mean difference 0.4 (95% CI 0.2–0.6)P < 0.001
Patient satisfaction score5.0 (interval 4.0–6.0)3.0 (interval 3.0–4.0)median difference 2.0 (95% CI 1.0–2.0)P < 0.001

Original publication

Transcutaneous electrical nerve stimulation and catheter-related bladder discomfort following transurethral resection of bladder tumour: A randomised controlled trial. Eur J Anaesthesiol. Published 13 August 2024. doi:10.1097/eja.0000000000002050

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.